Results 81 to 90 of about 4,313 (158)

Reply to Siddiqui et al., Godbout et al., and Chang and Mao. [PDF]

Am J Respir Crit Care Med
Chupp G, Nagase H, Skowasch D, Devouassoux G, Côté A, Jackson DJ, Jackson DJ, Wechsler ME, Howarth P, Pavord ID, all authors of ‘Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: a multicenter, randomized, double-blind, phase 3A clinical trial (NIMBLE)’ .   +13 more
europepmc   +1 more source

Efficacy and Safety of Biologic Therapies Targeting Type 2 and Epithelial-Alarmin Pathways in Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. [PDF]

Cureus
Khoshaim YA, Almaghrabi AR, Alruwaythi AA, Alotaibi AE, Alhoshan IM, Almalki TA, Sabbah AA, Al-Shuaibi AW, Almarzoqi ON, Mesawa OT, Alabdali A.   +10 more
europepmc   +1 more source

Exploring the Potential Benefits of Biologic Therapies Beyond Respiratory Allergy. [PDF]

Immunotargets Ther
Sica R, Catamerò F, Foti Randazzese S, Galletta F, Licari A, Marseglia GL, Mori F, Poto R, Pulvirenti F, Ricci S, Giovannini M, Manti S.   +11 more
europepmc   +1 more source

Benralizumab for Eosinophil-Related Cutaneous Adverse Events of Anticancer Therapy: A Phase II Trial. [PDF]

Clin Cancer Res
Lacouture ME, Pan A, Maier T, Chen A, Dranitsaris G, Shah NJ, Dang C, Gajria D, Gordon A, Iyengar N, Razavi P, Robson M, Rosen E, Wong S, Harris U, Ketosugbo K, Bravo C, Jain M, Markova A.   +18 more
europepmc   +1 more source

A four-year journey towards clinical remission and background therapies optimization with benralizumab: A retrospective analysis. [PDF]

World Allergy Organ J
Pini L, Bagnasco D, Beghè B, Braido F, Cameli P, Caminati M, Caruso C, Crimi C, D'Adda A, Guarnieri G, Latorre M, Menzella F, Vianello A, Visca D, Bondi B, El Masri Y, Giordani J, Mastrototaro A, Maule M, Pini A, Piras S, Zappa M, Senna G, Spanevello A, Paggiaro P, Blasi F, Canonica GW, SANI Study Groupu.   +27 more
europepmc   +1 more source

Sequential autoimmune and neoplastic manifestations during long-term benralizumab therapy for severe eosinophilic asthma: A descriptive case report. [PDF]

Respir Med Case Rep
Shimizu A, Hino M, Kubota K, Tanaka Y, Takeno M, Takei H, Terasaki Y, Seike M.   +7 more
europepmc   +1 more source

Efficacy and Safety of Biologic Therapies for Uncontrolled Asthma: An Overview of Systematic Reviews. [PDF]

Pediatr Pulmonol
Faria RJ, Bazoni PS, Santos JBRD, Silva ETD, Silva MRRD.   +4 more
europepmc   +1 more source

Impact of dose and administration schedule on biologic efficacy in chronic rhinosinusitis with nasal polyps: a network meta-analysis. [PDF]

Front Pharmacol
Khalifa MA, Ahmed Shimal A, Mahmoud MH, Roumi Jamal B, Atef P, Ali Ahmed MS, Khalil I, Alatise MB, Dway A, Irhayyif SR.   +9 more
europepmc   +1 more source

Response to benralizumab in patients with severe eosinophilic asthma. [PDF]

Rev Med Inst Mex Seguro Soc
Velasco-Santos JI, Núñez-Martínez FJ, Martínez-Sánchez BH, Chávez-Lárraga AJ.   +3 more
europepmc   +1 more source

Efficacy of Biologics in Patients with Moderate to Very Severe COPD: A Systematic Review. [PDF]

Int J Chron Obstruct Pulmon Dis
Brightling CE, Rabe KF, Singh D, Han MK, Bhutani M, Bourbeau J, Nair P, Drummond MB, Gandhi EA, Sindhwani NS, Molfino NA, Parulekar AD, Ponnarambil SS.   +12 more
europepmc   +1 more source